Skip to main content


Oncofertility refers to the medical field that bridges the specialties of oncology and reproductive endocrinology with the purpose of maximizing the reproductive potential of cancer patients and survivors. Oncofertility is therefore an interdisciplinary field at the intersection of oncology and reproductive medicine that expands fertility options for cancer survivors. Some cancer treatments, including chemotherapy, radiation, and surgery, can impair or destroy a person's ability to have children later in life. In women, these therapies can cause ovarian damage that can lead to genetic damage to oocytes, ovarian failure, early menopause, or other reproductive problems. In men, cancer treatments can similarly cause damage to the testes that interfere with sperm production and testosterone secretion. As cancer treatments improve and survivorship increases, fertility preservation options in women, men, and children have become an increasing important consideration. Fortunately, multiple treatment options exist to maximize your future fertility potential. Some of the fertility preservation options that we offer at Hudson IVF include:

detail of clean medical instruments in laboratory of fertility
  1. Ovarian transposition to protect ovaries from radiation therapy
  2. Therapeutic oophorectomy in patients with metastatic breast cancer
  3. Prophylactic oophorectomy in patients with BRCA1 or BRCA2 gene mutations
  4. Oocyte cryopreservation
  5. Emergency IVF
  6. Embryo banking
  7. Egg donation
  8. Ovarian Tissue Freezing
  9. Pre-implantation Genetic Diagnosis (PGD)
  10. Emergency IVF
  11. Embryo Banking
  12. Egg Donation
  13. Egg Banking
  14. Ovarian Tissue Freezing
  15. Sperm Banking
  16. Donor Sperm
  17. Testicular Sperm Extraction
  18. Testicular Tissue Freezing
  19. Ovarian Tissue Transplant

In his capacity as an Oncofertility specialist Dr Musha is a member of the Endocrine Society, the American Society of Reproductive Medicine, the Society for Reproductive Endocrinology and Infertility, the American Society of Clinical Oncology and the American Society of Gynecologic Oncology.  Dr Musha is also a member of the Oncofertility Consortium at Michigan State University (MSU).